Faculty Opinions recommendation of Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(08)79179-2 ◽

2009 ◽

Vol 2009 ◽

pp. 243-244

Author(s):

B.H. Thiers

Keyword(s):

Rheumatoid Arthritis ◽

Interleukin 6 ◽

Randomised Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Receptor Inhibition ◽

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Yearbook of Medicine ◽

10.1016/s0084-3873(09)79339-3 ◽

2009 ◽

Vol 2009 ◽

pp. 8-12

Author(s):

S.M. Berney

Keyword(s):

Rheumatoid Arthritis ◽

Interleukin 6 ◽

Randomised Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Receptor Inhibition ◽

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

The Lancet ◽

10.1016/s0140-6736(08)60453-5 ◽

2008 ◽

Vol 371 (9617) ◽

pp. 987-997 ◽

Cited By ~ 921

Author(s):

Josef S Smolen ◽

Andre Beaulieu ◽

Andrea Rubbert-Roth ◽

Cesar Ramos-Remus ◽

Josef Rovensky ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Interleukin 6 ◽

Randomised Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Receptor Inhibition ◽

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial

10.1002/art.10623 ◽

2002 ◽

Vol 46 (12) ◽

pp. 3143-3150 ◽

Cited By ~ 356

Author(s):

E. H. S. Choy ◽

D. A. Isenberg ◽

T. Garrood ◽

S. Farrow ◽

Y. Ioannou ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Dose Escalation ◽

Interleukin 6 ◽

Therapeutic Benefit ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 6 Receptor ◽

Receptor Monoclonal Antibody

Anti–interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled study

10.1002/art.21826 ◽

2006 ◽

Vol 54 (6) ◽

pp. 1778-1785 ◽

Cited By ~ 28

Author(s):

Rainer H. Straub ◽

Peter Härle ◽

Seizo Yamana ◽

Takemasa Matsuda ◽

Kiyoshi Takasugi ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Interleukin 6 ◽

Antibody Therapy ◽

Controlled Study ◽

Adrenal Androgen ◽

Double Blind ◽

Double Blind Placebo ◽

Receptor Antibody ◽

Interleukin 6 Receptor ◽

Androgen Secretion

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial

10.1002/art.20303 ◽

2004 ◽

Vol 50 (6) ◽

pp. 1761-1769 ◽

Cited By ~ 563

Author(s):

Norihiro Nishimoto ◽

Kazuyuki Yoshizaki ◽

Nobuyuki Miyasaka ◽

Kazuhiko Yamamoto ◽

Shinichi Kawai ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Interleukin 6 ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Receptor Antibody ◽

Double-Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist, Tocilizumab, in European Patients With Rheumatoid Arthritis Who Had an Incomplete Response to Methotrexate

Yearbook of Medicine ◽

10.1016/s0084-3873(08)70006-3 ◽

2007 ◽

Vol 2007 ◽

pp. 8-10

Author(s):

D.L. Kimpel

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Trial ◽

Receptor Antagonist ◽

Interleukin 6 ◽

Controlled Clinical Trial ◽

Randomized Controlled Clinical Trial ◽

Double Blind ◽

Randomized Controlled ◽

Incomplete Response ◽

Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants

10.1002/art.27740 ◽

2010 ◽

Vol 63 (1) ◽

pp. 43-52 ◽

Cited By ~ 91

Author(s):

Josef S. Smolen ◽

Daniel Aletaha

Keyword(s):

Rheumatoid Arthritis ◽

Acute Phase ◽

Interleukin 6 ◽

Acute Phase Reactants ◽

Disease Remission ◽

Receptor Inhibition ◽

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

10.1002/art.22033 ◽

2006 ◽

Vol 54 (9) ◽

pp. 2817-2829 ◽

Cited By ~ 520

Author(s):

R. N. Maini ◽

P. C. Taylor ◽

J. Szechinski ◽

K. Pavelka ◽

J. Bröll ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Trial ◽

Receptor Antagonist ◽

Interleukin 6 ◽

Controlled Clinical Trial ◽

Randomized Controlled Clinical Trial ◽

Double Blind ◽

Randomized Controlled ◽

Incomplete Response ◽

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia

Neuropsychopharmacology ◽

10.1038/npp.2017.258 ◽

2017 ◽

Vol 43 (6) ◽

pp. 1317-1323 ◽

Cited By ~ 29

Author(s):

Ragy R Girgis ◽

Adam Ciarleglio ◽

Tse Choo ◽

Gregory Haynes ◽

Joan M Bathon ◽

...

Keyword(s):

Clinical Trial ◽

Interleukin 6 ◽

Controlled Clinical Trial ◽

Double Blind ◽

Residual Symptoms ◽

Double Blind Placebo ◽

Receptor Antibody ◽